Malaria with other antimalarials (known as artemisinin-combination therapy, or ACT), which decreases resistance to any single drug component. These additional antimalarials include: amodiaquine, lumefantrine, mefloquine or sulfadoxine/pyrimethamine. Another recommended combination is dihydroartemisinin and piperaquine. ACT is about 90% effective when used to treat uncomplicated malaria. To treat malaria during pregnancy, the WHO recommends the use of quinine plus clindamycin early in the pregnancy (1st trimester), and ACT in later stages (2nd and 3rd trimesters). In the 2000s (decade), malaria with partial resistance to artemisins emerged in Southeast Asia. Infection with "P. vivax", "P. ovale" or "P. malariae" usually do not require
Clausena anisata half maximal effective concentration (EC50) value was 74 μg/mL. The authors concluded that these results encourage further investigation of the use of this plant as complementary treatment options for ascariasis. This species is used in treating an uncommonly wide range of ailments and conditions. Decoctions of the leaves or roots are taken for gastro-intestinal disorders, fever, pneumonia, headache, hypotension, sore throat and sinusitis, venereal diseases, as an aphrodisiac and anthelmintic, as a tonic for pregnant women, and as a tonic for infants to prevent rickets and to control convulsions. Root decoctions and infusions are also taken for whooping cough, malaria,